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Since it was introduced by Noon in 1911, allergen-speciﬁc immunotherapy or desensitization has been
widely prescribed in the management of allergic diseases. Aimed at the etiology, it represents the only
effective treatment for allergy.
The basic mechanisms of immunotherapy are becoming better understood and allow us to improve
this technique in the future. The sublingual immunotherapy as an alternative to subcutaneous route has
been widely studied. Several clinical trials conﬁrmed that sublingual immunotherapy is efﬁcient in
reducing allergic respiratory symptoms. The sublingual immunotherapy reduces the risk of developing
serious side effects due to desensitization.
We performed a literature review in order to remind the mechanisms of action and to demonstrate
efﬁcacy and tolerability of the sublingual immunotherapy in the treatment of allergic rhinoconjunctivitis
and asthma and its impact on the quality of life.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction to the management issues in the treatment of
allergic patients
Asthma, like others allergic respiratory diseases, is a frequently
encountered disease, and one that has a potentially serious impact
on patient’s function and quality of life (QOL). In the Maghreb
countries, the prevalence of asthma (3.4%e3.9%) is in the “low to
moderate” range as stated by the latest AIRMAG survey [1].
Nonetheless, this prevalence is expected to rise as the populations
become more urbanized and adopt a more ’Westernized’ lifestyle.
On the other hand, asthma control is unacceptably poor in theR14ES05, Interactions of the
dicine, University of Sousse,
issa), rahmarr757@yahoo.fr
nsalem.c@gmail.com (C. Ben
i), ahmed_benabdelghani@
(H. Ben Saad), mohamed.
. Boussarsar).
to this work.
rs to this work.
r Inc. This is an open access articleMaghreb [1]. This could be changed by improved access to appro-
priate treatments, more proactive patient follow-up and better
patient education. Furthermore, allergy is a highly prevalent clin-
ical condition. It can be managed by the simple avoidance of the
allergen, an anti-allergic such as antihistamines, a pathophysio-
logical treatment such as corticosteroids or simply symptomatic
treatment such as bronchodilators in case of asthma. Apart from
these treatments, immunotherapy offers the advantage of altering
the natural history of allergy by controlling the symptoms, reducing
the consumption of these drugs and especially preventing asthma
during the natural evolution of a rhinitis or better sustaining efﬁ-
ciency or preventing other sensitizations.
The allergen-speciﬁc immunotherapy is an effective therapeutic
option in cases selected by rhinitis and/or by atopic asthma. Se-
lection is mainly made by taking into account patients’ individual
factors such as disease severity, efﬁcacy of avoidance measures,
pharmacological therapy and patients’ preferences. Allergen-
speciﬁc immunotherapy is the process of administering
increasing amounts of allergen(s) to allergic subjects in order to
achieve hypo-sensitization that is to reduce the symptoms occur-
ring during the natural exposure to the allergen itself. The history ofunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
S. Aissa et al. / Contemporary Clinical Trials Communications 4 (2016) 1e82allergen-speciﬁc immunotherapy began in the ﬁrst years of the
twentieth century. In fact, Noon aimed at achieving a vaccination
against “airborne toxins,” and for this reason he chose, although
unfunded, the subcutaneous route of administration [2]. Subcu-
taneous immunotherapy (SCIT) has been the conventional mode of
therapy for patients with seasonal allergic rhino-conjunctivitis
(ARC) and milder asthma that is unresponsive to pharmaco-
therapy [3]. With continued administration, it is expected that the
treatment regimen will make the patient tolerant to the offending
allergen and suppress future undesired responses to the allergen(s)
through modulation of the patient’s immune system [4,5]. How-
ever, this effective form of treatment is hindered by: 1/A prolonged
injection schedule, 2/Patient non-compliance due to the frequent
visits to the physician needed by the regimen and the delayed
impact on the symptoms, 3/The discomfort associated with in-
jections and, 4/The recognized risk of severe allergic reaction
[3,6e8].
During the same period, allergy management included new
effective symptomatic and pathophysiologic drugs (b-agonists,
corticosteroids, chromones, anti-leukotriene drugs) which
demonstrated their efﬁciency on symptoms and QOL among
allergic patients. In addition, there was a received idea stating that
immunotherapy would not be effective particularly among older
subjects.
Adding to these considerations, the SCIT, which is fundamen-
tally criticizable, suffers from a poor acceptability, constraining
young active patients to move to receive their injections. All these
considerations have rapidly created a breach for the introduction of
the sublingual immunotherapy (SLIT) in 1986 after a long e lasting
oversight because of miscellaneous impediments.
SLIT involves desensitization by placement of the allergen
extract under the tongue as an aqueous solution or as a dissolvable
tablet for local absorption. SLIT was considered to be a better
treatment modality associated with less severe systemic adverse
effects and better compliance, but there is no demonstration that
SLIT has additional mechanisms of action compared with SCIT. The
use of SLIT provides an attractive option, for outpatient, home-
based and self-administered therapy. The efﬁcacy of SLIT has
been demonstrated in children with allergic rhinitis and asthma,
and the progression of atopy was reduced [9,10]. SLIT seems to be
more appropriate because of its safety, tolerable adverse effects,
and good compliance [9e11]. However, recent data are conﬂicting.
Indeed, the recent Cochrane meta-analysis for asthma [12]
concluded that “lack of data for important outcomes such as ex-
acerbations and QOL and use of different unvalidated symptom and
medication scores have limited our ability to draw a clinically useful
conclusion. Further research using validated scales and important
outcomes for patients and decision makers is needed so that SLIT
can be properly assessed as a clinical treatment for asthma”.
2. Review of the SLIT, pharmacology and mode of action
At optimal doses SLIT demonstrates effective. It could induce
disease remission after discontinuation and may prevent new
sensitization. These features are consistent with the induction of
tolerance. In comparison with the subcutaneous immunotherapy,
SLIT provides an additional local mechanism in oral mucosa and/or
regional lymph nodes and leads to less systemic effects [8].
2.1. Pharmacology
The SLIT in suspension, as injectable allergen immunotherapy, is
developed specially for every individual and prepared by the lab-
oratory on a practitioner’s prescription and sent directly to the
patient.For tablets, two specialties are available: i) Grazax® (75,000 SQ-
T, oral Lyophilisat allergenic extracted standardized by pollen of
grass of phleole of the meadows (Phleum pratense), having ob-
tained a marketing authorization for the allergic rhinoconjuncti-
vitis to pollens of grasses) is available in pharmacy and delivered on
prescription [13] and ii) Oralair® (allergenic extract of pollens:
Dactylis glomerata L, Lolium perenne L, Anthoxanthum odoratum L,
Poa pratensis and Phleum pratense L), which has a European
marketing authorization [14].
These pharmaceutical forms allow an excellent reproducibility
of the dose administered to every grip and do not impose the
constraints of preservation in a cooled place as the solutions of
allergens.
2.2. Mode of action
Information on the mechanisms of SLIT is less well-advanced.
However, there is considerable knowledge regarding mechanisms
of SCIT [15,16]. For this reason, we aimed at exposing an overview of
the SLIT mechanism of action.
2.3. Immunomodulation during the SLIT
It is now admitted that the efﬁciency of the desensitization is
connected to the reorientation of the system Th2 (Th for T helper
cells) towards the system Th1 and relying on the modulation of
immune responses by speciﬁc regulating T-cells of the allergen [17].
The immune response in the atopic patient is characterized by a
high production of type Th2 cytokines (IL4, IL5 and IL13, IL for
interleukin) and by T-cells CD4þ (CD for cluster of differentiation)
speciﬁc of the allergen [18,19].
This cytokinic proﬁle results in the secretion of speciﬁc immu-
noglobulin E (IgE) by B lymphocytes, as well as the recruitment and
the activation of mastocytes, basophilic and eosinophilic cells
which release mediators of the inﬂammation (histamine, tryptase,
prostaglandins, leukotrienes, etc.) at the level of target organs
[19,20].
The SLIT, as well as SCIT, acts at the same time on humoral and
cell mechanisms of the immune system involved in the allergic
reaction [15,21].
The SLIT leads to an increase in the production of allergen
speciﬁc IgG4 and consequently to a limited impact on the pro-
duction of the IgE. The correlation between the ratio IgE/IgG4 and
the clinical efﬁciency of the immunotherapy was controversial
[22e25].
During the SLIT, we also observe a decrease in the recruitment of
the pro-inﬂammatory cells (basophilic and eosinophilic) on the
level of the skin, the nose, the eyes and the bronchial mucous
membrane as well as an inhibition of their activation, leading to a
signiﬁcant reduction in the release of the pro-inﬂammatory me-
diators [26,27].
The effect of the SLIT on the differentiation and the polarization
of the allergen speciﬁc lymphocytic response TCD4þ is less well-
documented than for the SCIT.
2.4. Role of the lymphocyte T regulator
Paradigm exchange of the speciﬁc immunotherapy aimed for a
long time at redirecting the lymphocytic answers Th2 against the
allergen towards an answer of type Th1 [28,29].
The induction of allergen speciﬁc regulating T-cells (T Reg)
inhibiting at the same time the answers Th1 and Th2 represents a
hypothesis favored in the conception of new immunotherapeutic
treatments nowadays [30e32].
Two categories of regulating cells were described according to
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by the expression of the factor of transcription Foxp3, and deriving
from the thymus [34]. 2/T-cells adaptive Reg which acquire their
immunosuppressive activity after precursor’s activation T in-
nocents (naive painters) of the peripheral blood [35]. Among the
latters, a subgroup of lymphocytes Tr1 seems to play a major role.
Lymphocyte Tr1 is dominant in the healthy subjects, tolerating the
allergen. Their presence would be dominating in the initial phases
of the allergen immunotherapy and the increase of these cells and
their mediators (IL-10, Transforming growth factor b (TGF-b)) was
noticed in the blood and in the peripheral organs as the nasal
mucous membrane in patients desensitized.
During the allergen immunotherapy, modiﬁcations are also
observed in lymphocytic B populations. The speciﬁc IgE of the
allergen increases in the beginning of desensitization then tend to
decrease secondarily. The synthesis of speciﬁc IgG4 and IgG1 of the
allergen was able to be observed during the desensitization. The
increase of the latter, as well as a serum factor blocking the ﬁxation
of the IgE in allergens, seemed to correlate in the clinical
improvement of a group of asthmatic patients desensitized in the
dust mites of house [36].
The IL-10, one of the key cytokines secreted by lymphocytes Tr1,
plays a role in the orientation of the of B lymphocytes secretion
proﬁle towards the synthesis of IgG4 rather than that of the IgE.
As such, the IL-10 would be a powerful modulator of the toler-
ance, acting at the same time on the total IgE and on the speciﬁc IgE,
with a ﬁnal decrease of the ratio IgE/IgG4.
2.5. Speciﬁcity and pharmacodynamics of the buccal immune
system
2.5.1. General diffusion
The bottom of the tongue being much vascularized, blood ves-
sels stream directly in the jugular vein. So, the small molecules
administered by a sublingual way quickly reach the general circu-
lation shunting the bowel or the liver [31,32]. The obtained plas-
matic concentration is maximal approximately 5 min after
administration, with a global bioavailability of about 70% [37,38].
2.5.2. Local diffusion
The local environment in the mouth is regarded as a site of
natural immune tolerance [15].
During the SLIT, the dendritic cell captures the allergen, in the
site of the deposit on the buccal mucous membrane, in a few mi-
nutes. Then these cells run in the proximal lymph nodes, where
they stimulate naive helper lymphocytes CD4þ. The buccal mucous
membrane contains a large number of dendritic cells of expressing
receptors of high (RFceRI) and low (CD23) afﬁnity for the IgE. These
receptors may facilitate the capture of the allergen, and lead to the
production of IL10, of TGF-b and an enzyme which catabolizes the
tryptophan, leading to a decrease in the proliferation of lympho-
cytes T [39,40].
The lymphocytic population and the local rates of IL10, TGF-b
and interferon d in this region of the mucous membrane appear to
be more important than on the skin, suggesting a strong tolerogen
power of this zone.
3. Efﬁcacy studies and comparison to standard therapies
3.1. Efﬁcacy on symptoms
During the last decade, many prospective trials have been made
to study the efﬁcacy of SLIT. These trials suffered from some limi-
tations especially sample size and heterogeneity. This led to many
meta-analyses and systematic reviews (Table 1).The ﬁrst meta-analysis of SLIT, performed in 2005 by Wilson
et al. [41], addressed only allergic rhinitis because the studies about
allergic asthma were too scarce to perform a meta-analysis. It
included 22 trials among 979 patients. Studies were very hetero-
geneous according to the allergen studies. Overall there was a
signiﬁcant reduction in both symptoms (standardized mean dif-
ference (SMD) [95% conﬁdence interval (95%CI)], 0.34 [0.69,
0.15]) and medication requirements (SMD [95%CI], 0.43 [0.63,
0.23]) following immunotherapy.
Another meta-analysis of allergic rhinitis in pediatric patients,
including 10 trials and 484 subjects, was performed by Penagos
et al. [42]. It showed that SLIT was signiﬁcantly more effective than
placebo and demonstrated a signiﬁcant reduction in both symp-
toms, (SMD [95%CI], 0.56 [1.01, 0.10]) and medication use (SMD
[95%CI], 0.76 [1.46, 0.06]) after immunotherapy.
Regarding asthma, a meta-analysis by Calamita et al. [43]
included 25 trials (either open or blinded) that involved 1706
adults and children. This meta-analysis found that SLIT was bene-
ﬁcial for asthma treatment albeit the magnitude of the effect was
not very large. Moreover, it proved to be a safe alternative to the
subcutaneous route.
Anothermeta-analysis by Penagos et al. [44] was also performed
for asthma in pediatric patients. It included nine double-blind,
placebo-controlled (DBPC) trials and 441 patients, and found a
signiﬁcant effect of SLIT on both asthma symptoms and rescue
medication usage. However, it suffered from consistent heteroge-
neity due to various rating systems. The analysis demonstrated
signiﬁcant reduction in both symptoms after SLIT, (SMD [95%CI],
1.14 [2.10, 0.18]) and medication use (SMD [95%CI], 1.63
[2.83, 0.44]). Authors concluded that SLIT with standardized
extracts induces a reduction in both symptoms and need for rescue
medication among asthmatic children in comparison with placebo.
The meta-analyses mentioned above, pooled together all the
allergens. Although SLIT appeared globally effective, the sub-
analyses for single allergens provided uncertain results. Never-
theless, it is noteworthy that when a systematic evaluation of the
efﬁcacy was restricted to one speciﬁc allergen (house dust mite,
HDM), the results remained positive [45]. Although authors
detected a relevant inter-study heterogeneity, promising evidence
of efﬁcacy for SLIT, using mite extract in allergic patients suffering
from allergic rhinitis and allergic asthma, was shown. It suggested
that more data derived from high-quality studies based on large
population are needed and should be corroborated by objective
outcomes, mainly for allergic asthma.
In summary, these meta-analyses involved very heterogeneous
trials, often without a proper sample size calculation. Publication
biases and discrepancies in data collection were additional con-
cerns [46]. Thus, they provided only suggestive evidence.
More recent systematic review by Radulovic et al. [47] included
60 studies among 4589 patients with rhino-conjunctivitis. Forty
trials involved pollen SLIT. This publication conﬁrms the efﬁcacy of
SLIT on standard evaluation criteria of allergic rhinitis, as well as on
the symptom score and drug consumption. For eye symptoms, a
meta-analysis by Calderon et al. [48] of 46 studies using sublingual
(suspension or tablets) route showed that it was effective on the
overall score of ocular symptoms and scores of individual symp-
toms (watery eyes, itchy eyes…).
A recent comprehensivemeta-analysis by Lin et al. [49] included
63 studies with 5131 participants aged 4e74 years. Twenty studies
(n ¼ 1814 patients) involved only children. The risk of bias was
medium in 43 studies (68%). Strong evidence supports that SLIT
improves asthma symptoms, with 8 out of 13 studies reporting
more than 40% of improvement vs. the comparator. Moderate evi-
dence supports that SLIT use decreases rhinitis or rhino-
conjunctivitis symptoms, with 9 of 36 studies demonstrating
Table 1
Summary results of meta-analyses of studies on sublingual immunotherapy efﬁcacy.
Author
[Reference]
Journal
Year
Study design Studies
(n)
Population Patients
(n)
Disease Allergens Main results
Wilson DR
[41]
Allergy
2005
Systematic
review and
meta-analysis
22 Adults and
children
979 Allergic rhinitis House dust mite, grass pollen,
parietaria, olive, ragweed, cat,
tree cupressus
Symptoms: 0,34 [0.69, 0.15]a; p ¼ 0.002
Medication requirements: 0,43 [0.63, 0.23]a;
p ¼ 0.00003
Penagos M
[42]
Ann Allergy
Asthma
Immunol
2006
Meta-analysis 10 Children 484 Allergic rhinitis Pollen, mite Symptoms: 0,56 [1.01, 0.10]a; p ¼ 0.02
Medication use: 0,76 [1.46, 0.06]a; p ¼ 0.03
Calamita Z
[43]
Allergy
2006
Systematic
review and
meta-analysis
25 Adults and
children
1706 Asthma Pollen, mite, latex, dander,
mould
64% of studies: signiﬁcant reduction of asthma severity
Penagos M
[44]
Chest
2008
Meta-analysis 9 Children 441 Allergic asthma
With/without
rhinitis or rhino-
conjunctivitis
Mite, holcus, P pretense
dermatophagoides
pteronyssinus, grass mix,
europaea
Symptoms: 1.14 [2.10, 0.18]a; p ¼ 0.02
Medication use: 1.63 [2.83, 0.44]a; p ¼ 0.007)
Radulovic S
[47]
Allergy
2011
Cochrane
systematic
review
60 Adults and
children
4589 Allergic rhinitis
and/or
conjunctivitis
and/or asthma
ragweed, grass, parietaria, tree,
house dust mite
Symptoms: 0.49 [0.64, 0.34]a; p < 0.00001
Medication requirements: 0.32 [0.43, 0.21]a;
p < 0.00001
Calderon
MA [42]
Clinical &
Exp
Allergy
2011
Cochrane
systematic
review and
meta-analysis
42 Adults and
children
3958 Allergic rhino-
conjunctivitis
e Total ocular symptom scores: 0.41 [0.53, 0.28]a;
p < 0.00001
Lin SY [49]
JAMA
2013
Systematic
review
63 Adults and
children
5131 Allergic rhino-
conjunctivitis
and Asthma
Dust mite, alternaria, grass mix,
tree mix, birch, parietaria,
ragweed, cat, olive, cedar,
timothy grass
Moderate evidence supports that sublingual
immunotherapy use decreases rhinitis or
rhinoconjunctivitis symptoms, with 9 of 36 studies
demonstrating greater than 40% improvement vs the
comparator.
Wu YY [50]
Zhonghua
Nei Ke
Za Zhi
2013
Meta-analysis 6 e e Allergic asthma Asthma symptom scores: 0.89 [1.36, 0.43]a;
p ¼ 0.0001
Asthma medication scores: 4.53 [6.97, 2.08]a;
p ¼ 0.0001
FEV1: 0.19 [0.02, 0.41]a; p ¼ 0.078
Serum IgE level: 0.05 [0.58, 0.69]a; p ¼ 0.870
Tao L [51]
Clin Respir J
2014
Meta-analysis 16 Adults and
children
794 Allergic asthma Mite Symptoms: 0.74 [1.26, 0.22]a; p ¼ 0.006
Medication scores: 0.78 [1.45, 0.11]a; p ¼ 0.02
Normansell
R [12]
Cochrane
Database
Syst Rev
2015
Systematic
review
Meta-analysis
52 Adults and
children
5077 Asthma with any
allergen-
sensitization
pattern
House dust mite, pollen extract Changes in inhaled corticosteroid use in micrograms per
day: 35.10 [50.21, 120.42]b; low-quality evidence
Bronchial provocation: 0.69 [0.04, 1.43]a; very low
quality evidence
FEV1, First second forced expiratory volume; IgE, Immunoglobulin E.
a Data are standardized mean difference [95% conﬁdence interval].
b Data are mean difference [95% conﬁdence interval].
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for asthma and allergies, decreased by more than 40% in 16 out of
41 studies of SLIT, with moderate grade evidence. Moderate evi-
dence supports that SLIT improves conjunctivitis symptoms (13
studies), combined symptom and medication scores (20 studies),
and disease-speciﬁc QOL (eight studies).
Another meta-analysis byWu et al. [50] evaluated the efﬁcacy of
SLIT in patients with allergic asthma in order to provide reliable
evidence for clinical application of SLIT. It showed that, compared
with control group, SLIT could signiﬁcantly reduce asthma symp-
tom scores (SMD [95%CI], 0.89 [1.36, 0.43]) and asthma
medication scores (SMD [95%CI],4.53 [6.97,2.08]), but neither
ﬁrst second forced expiratory volume (FEV1) (SMD [95%CI], 0.19
[0.02, 0.41]; p ¼ 0.078), nor serum IgE levels (SMD [95%CI], 0.05
[0.58, 0.69]; p ¼ 0.870).A meta-analysis by Tao et al. [51] was performed to investigate
the clinical efﬁcacy and safety of SLIT for allergic asthma. Sixteen
randomized DBPC trials, with a total of 794 patients, suggested that
SLIT signiﬁcantly reduces both symptom scores (SMD [95%CI],
0.74 [1.26, 0.22]) and medication scores (SMD [95%CI], 0.78
[1.45, 0.11]) compared with placebo. SLIT clinical response was
more efﬁcient in mite sensitive asthmatics. Prolonged duration of
treatment for more than 12 months proved to bring no additive
effects. Immunotherapy has also improved the skin prick test, but
there was no consistent effect on FEV1, antigen speciﬁc sIgG4, and
sIgE. The relative risk of adverse effects was 2.23 (p ¼ 0.01).
In the 2015 systematic review and meta-analysis by Normansell
et al. [12] including 5077 asthmatics, the SLIT effects on changes in
inhaled corticosteroid use and bronchial provocation were quali-
ﬁed, respectively, as low and very low quality evidence.
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Allergy is not a static entity, but it could evolve in its clinical
presentation over time. In some patients, this entity was addressed
to as the so called “atopic march”. Thus it is well known that allergic
rhinitis often precedes asthma [52e57] or the development of
bronchial hyperreactivity [58,59]. Another aspect of the natural
history of respiratory allergy is the trend to develop new sensiti-
zations over time [59].
The effect on natural history of respiratory allergy was described
with SCIT more than 40 years ago [60e67]. Because the ﬁrst clinical
trials with SLIT aimed at demonstrating efﬁcacy and safety, the
disease modifying effects have only been addressed over the past
10 years.
The ﬁrst study showing that SLIT may prevent the onset of
asthmawas published in 2004 [68]. After three years, development
of asthma was 3.8 (95%CI, [1.5, 10]) times more frequent in the
control subjects. These results were conﬁrmed in another study
that demonstrated that asthma occurrence was reduced from 30%
in controls to 1.5% in SLIT group, with a number of four cases to be
treated. Other studies demonstrated that SLIT was also capable of
preventing the onset of bronchial hyperreactivity to methacholine
[69,70].
Other randomized controlled trials suggested a preventive effect
on new skin sensitizations with SLIT. In 511 patients randomly
submitted to SLIT or drugs alone, Marogna et al. [71] demonstrated
that new sensitizations appeared in 38% vs. 5.9% respectively in
control vs. SLIT patients.
Another clinical effect of SLIT on the natural history of allergy is
the long-lasting effect. Indeed, several studies largely demon-
strated that a 3e4 years course of SLIT represents the best combi-
nation of clinical efﬁcacy and a long term effect was observed up to
seven years after discontinuation [11,72e74].
3.3. SLIT vs. SCIT
As stated before, many systematic reviews and meta-analyses
on allergen immunotherapy have been conducted in recent years
(Table 1). However, direct comparisons of subcutaneous and sub-
lingual immunotherapy were rare. This may be the result of the
reluctance of manufacturers to conduct such studies, or rather
because of the methodological aspects of double blinding.
In 2009, the World Allergy Organization (WAO) reported a re-
view of randomized controlled trials dealing with a comparison
between SCIT and SLIT [8]. In fact, only two studies were double-
blind double-dummy [75,76]. One of these, carried out by Khinchi
et al. [76], was placebo controlled and demonstrated that symp-
toms and medication use were reduced by about one third in the
SLIT group and by a half in the SCIT group. Overall analyses
concluded to no difference between the two treatments. The four
remaining trials [77e80] were all conducted in an open fashion.
In another systematic review conducted by Chelladurai et al.
[81], eight studies have been included. All of them were head to
head but only three included controls [76,78,82]. This review also
included the well done study by Khinchi et al. [76]. Authors
concluded that the review provides low-grade evidence showing
that SCIT is superior to SLIT in asthma symptom reduction and
moderate-grade evidence showing reduction in rhino-
conjunctivitis [81].
A more recent and innovative systematic review by Detzke et al.
[83] included respectively 17 placebo controlled randomized
controlled trials for SCIT and 11 for SLIT. Only one study was head to
head trial (the one by Khinchi et al. [76]). The originality of this
review was to proceed to indirect comparisons of placebo
controlled studies respectively with SLIT or SCIT. The advantage isto avoid the huge proportion of drop-outs in head to head studies as
in the one by Khinchi et al. [76] or all the other studies included in
the review by Chelladurai et al. [81]. The indirect comparison
favored SCIT over SLIT in terms of symptom score but not in terms
of the combined symptom medication or QOL. Authors concluded
that despite evidence of efﬁciency of both SLIT and SCIT, the su-
periority of one over the other could not be proven through indirect
comparison [81].
From another inception, a study carried out in Asia in 2011
showed that SLIT has been establishing its role for allergic rhinitis
[84]. Long-term use of SLIT could alter immunologic proﬁles. SLIT,
as well as SCIT, also prevents poly-sensitization and development of
asthma. It also demonstrated that there seems to be less risk of
severe or fatal adverse events than in SCIT [85].
Since the consensus of the WAO in 1988 [8], several meta-
analyses were conducted to prove the efﬁcacy of SLIT, and are
regularly updated by different organizations and scientiﬁc societies
(ARIA: Allergic Rhinitis and its Impact on Asthma, EAACI: European
Academy of Allergy and Clinical Immunology, AAAAI: American
Academy of Allergy, Asthma & Immunology).
4. Safety and tolerability
While large scale randomized DBPC trials, position papers, and
meta-analyses have emphasized the efﬁcacy of SLIT, safety has been
less addressed [8,46,86,87]. One of the suggested advantages of
SLIT over SCIT is its greater safety, which would allow its admin-
istration outside the medical ﬁeld. It has been demonstrated that
while both are equally efﬁcient, SLIT leads to “less” and “less se-
vere” adverse events than SCIT [75e80,88]. Compared to SCIT, SLIT
is generally considered to have a better safety proﬁle. In SLIT, most
reactions are local and transient and do not lead to interruption or
cessation of treatment [89].
In a comprehensive review of 104 articles dealing with SLIT,
information on safety and tolerance were provided by 66 studies
conducted on 4378 patients receiving about 1,181,000 SLIT doses
[89]. The amount of information on the adverse events in these
studies varied greatly, ranging from general summary statements,
such as “no relevant side effects,” to a detailed analysis of the
adverse events [90]. Because of the vast heterogeneity in classifying
and reporting SCIT adverse events, some efforts have been made to
develop a uniform severe reactions grading system [90].
SLIT adverse events were frequently local (75%) and 0.06% of
doses administered were classiﬁed as severe reactions. The ma-
jority of these reactions were gastrointestinal symptoms, rhino-
conjunctivitis, urticaria, or some combination of these symptoms
[91].
The SLIT comprehensive review [89], reported neither fatalities
nor anaphylactic reactions. However, there were 14 probable SLIT-
related serious adverse events (SAE) in 3984 patients treated with a
total of 1,019,826 doses in 58 studies. This represents 1.4 SAEs per
100,000 SLIT doses and one SLIT-related SAE per 384 treatment
years or 285 patients. Asthmatic reactions were the most common
SLIT-related SAE. Abdominal pain and vomiting (n ¼ 3), uvula
edema (n ¼ 1) and urticaria lasting 48 h were also reported [89].
Subsequent to these data, some cases of severe adverse events
associated with anaphylaxis were reported with SLIT [92e95].
5. Patient focused perspectives such as QOL, patient
satisfaction and acceptability
5.1. Adherence
Adherence (acceptance and persistence) to treatment is often a
problem in chronic conditions, particularly with SLIT in asthma and
S. Aissa et al. / Contemporary Clinical Trials Communications 4 (2016) 1e86rhinitis where treatment has no immediate impact on symptoms.
Subcutaneous and sublingual approaches differ signiﬁcantly in
terms of determinants of adherence (related medical/hospital
administration for SCIT, by the patient for the SLIT), although few
data are published.
A multicenter observational study by Lombardi et al. [96] was
speciﬁcally designed to provide a quantitative measure of SLIT
adherence. Eighty-six patients with allergic rhinitis, asthma, or
both were treated by SLIT. Adherencewas about 97% for all patients.
Omitted doses were reported in 11 patients, with most of who
postponed one or two doses because of concurrent illness or
forgetfulness. One patient skipped multiple doses because of work
schedule [96].
In a randomized, 4-year open study of 511 patients with allergic
rhinitis, asthma, or both caused by various allergens, adherence to
SLIT over the 3-year period was excellent (>80%), good (from 60% to
80%) and poor or insufﬁcient (<60%), respectively in, 72%, 18% and
10% of the 271 included patients [97].
In another study, Passalacqua et al. [98] demonstrated that at
three months, 85% of subjects had a compliance rate >75% (69% of
them adhered >90%). At six months, 84% had a compliance rate
>75% (66% of them adhered >90%) [98].
Canonica et al. [99] demonstrated that the cost of allergen given
via sublingual route was found to be high. Nevertheless, this was
balanced by a reduced need for medical and nursing time and by
the absence of the cost of injections. Taking into account all these
aspects, the global cost of SLIT is even lower than that of SCIT [99].
A recent study by Incorvaia et al. [100] concluded that after the
ﬁrst optimistic reports in recent years on a very high adherence to
SLIT, it became apparent that SLIT is plagued by the same issue of
low adherence that affects drug treatment. The degree of adher-
ence is particularly low in the third year of SLIT, and this prevents
the disease-modifying effect on the natural history of allergy from
being achieved, the occurrence of which ensures the long-lasting
clinical beneﬁts and the consequent pharmaco-economic advan-
tages [100]. The search for optimal adherence is a question of
balancing a number of factors. Improving adherence to SLIT is a
major goal, and the recent studies suggest that patient education,
accurate monitoring during treatment and possibly technology-
based tools are interventions that are likely to meet such a need
[100].
5.2. Quality of life
In a randomized double blind study, authors demonstrated that
SLIT added to a combination of grass and olive pollen extracts was
better tolerated when given directly in the maintenance phase
[101]. These results agree with those reported by a previous
multicenter study conducted without up dosing [102]. It demon-
strates a clinically signiﬁcant improvement in QOL with rhinitis
overtime of 1.42 (>0.5 the smallest clinically relevant value, as
stressed by Guyatt and Jaescheke [103] and proposed in the ques-
tionnaire of Juniper et al. [104,105].
In another study by Ciprandi et al. [106], the effect of SLITon QOL
was clinically relevant to activities, practical problems, and nasal
and ocular symptoms. This is interesting as these are the aspects
that have proved to be affected most in allergic rhinitis [106].
In a study by Morris et al. [107], SLIT was demonstrated to be
effective in reducing symptoms and improving QOL after a four-
months of treatment. This improvement was most prominent in
activity, non-nose/eye symptoms, nasal symptoms, and emotional
domains. Improvement in the sleep domain of the rhino-
conjunctivitis quality of life questionnaire (RQLQ) was also
observed, but did not reach statistical signiﬁcance. This improve-
ment was sustained and demonstrated again at 10e12 months oftreatment. Taking into account the high compliance rates and the
La Crosse Method, it is expected that the improvement achieved is
likely to be sustained and possibly expanded beyond the ﬁrst year
of ongoing treatment [107].
In another study by Wise et al.[108], paired mini-RQLQ results
revealed statistically a signiﬁcant improvement on 12 of 14 do-
mains assessed by this questionnaire [108]. Improvements in the
impact on regular and recreational activities, sleep, nose rubbing
and nose blowing, stuffy nose and runny nose, itchy eyes, sore eyes,
watery eyes, thirst, and tiredness were seen. Total mini-RQLQ score
also showed statistically signiﬁcant improvement, with a decrease
in mean score from 27.8 before initiation of SLIT to 12.6 during the
maintenance phase of therapy.
6. Conclusion
Sublingual allergen speciﬁc immunotherapy, an aetiology-based
treatment for respiratory allergic diseases, is gaining an accumu-
lating evidence of efﬁcacy and safety compared to the subcutane-
ous classic route of administration. In some European countries, it
is currently used more frequently. When administrated at high
doses regularly for at least three consecutive years, SLIT could
demonstrate some advantages over SCIT: 1/Better tolerance with
only local reactions, 2/Better compliance and better QOL. The het-
erogeneity of trials involved in meta-analyses, the use of different
allergens, the publication biases and discrepancies in data collec-
tions provided only suggestive evidence of the superiority of SLIT
over SCIT. Further well-designed randomized controlled trials are
needed to support this evidence base for clinical decision-making.
These trials would focus especially on optimal patient selection,
dosage, protocol and treatment duration.
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